Clinical Trial Update: Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2') [Phase 2]

View source ↗

Summary

Phase 2 trial investigating pembrolizumab with paclitaxel for hormone receptor-positive, hypermutated metastatic breast cancer identified by whole exome sequenc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Yonsei University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN